Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6078MR)

This product GTTS-WQ6078MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6078MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11196MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ9602MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3240MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ3834MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ14425MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ947MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ13892MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ5239MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW